Scientific opinion on the tolerable upper intake level for manganese
Authors:
- Novel Foods And Food Allergens (Nda) Efsa Panel On NutritionNNNovel Foods And Food Allergens (Nda) Efsa Panel On Nutrition
- Dominique TurckDTDominique Turck
- Torsten BohnTBTorsten Bohn
- Jacqueline CastenmillerJCJacqueline Castenmiller
- Stefaan de HenauwSHStefaan de Henauw
- Karen‐Ildico Hirsch‐ErnstKHKaren‐Ildico Hirsch‐Ernst
- Helle Katrine KnutsenHKHelle Katrine Knutsen
- Alexandre MaciukAMAlexandre Maciuk
- Inge MangelsdorfIMInge Mangelsdorf
- Harry J. McArdleHMHarry J. McArdle
- Kristina PentievaKPKristina Pentieva
- Alfonso SianiASAlfonso Siani
Open Access
- 1 December 2023
- journal article
- research article
- Published by Wiley in EFSA Journal
- Vol. 21 (12) , e8413
Abstract
Following a request from the European Commission (EC), the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver a scientific opinion on the tolerable upper intake level (UL) for manganese. Systematic reviews of the literature of human and animal data were conducted to assess evidence regarding excess manganese intake (including authorised manganese salts) and the priority adverse health effect, i.e. manganese‐induced neurotoxicity. Available human and animal studies support neurotoxicity as a critical effect, however, data are not sufficient and suitable to characterise a dose–response relationship and identify a reference point for manganese‐induced neurotoxicity. In the absence of adequate data to establish an UL, estimated background dietary intakes (i.e. manganese intakes from natural dietary sources only) observed among high consumers (95th percentile) were used to provide an indication of the highest level of intake where there is reasonable confidence on the absence of adverse effects. A safe level of intake of 8 mg/day was established for adults ≥ 18 years (including pregnant and lactating women) and ranged between 2 and 7 mg/day for other population groups. The application of the safe level of intake is more limited than an UL because the intake level at which the risk of adverse effects starts to increase is not defined.Keywords
This publication has 279 references indexed in Scilit:
- Manganese transport via the transferrin mechanismNeuroToxicology, 2013
- Mutations in SLC30A10 Cause Parkinsonism and Dystonia with Hypermanganesemia, Polycythemia, and Chronic Liver DiseaseThe American Journal of Human Genetics, 2012
- Manganese exposure from drinking water and children's academic achievementNeuroToxicology, 2012
- Ingestion of Mn and Pb by rats during and after pregnancy alters iron metabolism and behavior in offspringNeuroToxicology, 2011
- Manganese exposure induces microglia activation and dystrophy in the substantia nigra of non-human primatesNeuroToxicology, 2011
- Biomarkers of manganese intoxicationNeuroToxicology, 2011
- Preweaning Mn exposure leads to prolonged astrocyte activation and lasting effects on the dopaminergic system in adult male ratsSynapse, 2010
- Preweaning manganese exposure causes hyperactivity, disinhibition, and spatial learning and memory deficits associated with altered dopamine receptor and transporter levelsSynapse, 2009
- Postnatal manganese exposure alters dopamine transporter function in adult rats: Potential impact on nonassociative and associative processesNeuroscience, 2008
- Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1European Journal of Pharmacology, 2008